ZHAOKE OPHTH-B (06622) announced that it has entered into a distribution and supply agreement with leading Indonesian pharmaceutical company PT Ferron Par Pharmaceuticals ("PT Ferron") for the commercialization of BRIMOCHOL™ PF in Indonesia. BRIMOCHOL™ PF is an innovative drug licensed by Tenpoint Therapeutics, Ltd. ("Tenpoint") for the treatment of presbyopia.

Under the agreement, ZHAOKE OPHTH-B grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia. The company will receive an upfront payment and may earn additional milestone payments based on specific achievements.

In June 2025, Tenpoint, the developer of BRIMOCHOL™ PF, announced that the U.S. FDA had accepted the New Drug Application (NDA) for the product. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 28, 2026, for BRIMOCHOL™ PF.

BRIMOCHOL™ PF is a preservative-free, once-daily experimental eye drop designed to correct age-related loss of near vision. The BRIO-II study was a three-arm, multicenter, randomized, double-blind safety and efficacy trial comparing BRIMOCHOL™ PF (a fixed-dose combination of carbachol and brimonidine tartrate), carbachol monotherapy, and vehicle eye drops in patients with presbyopia (NCT05135286). The study enrolled 629 subjects across 47 U.S. trial sites.

PT Ferron Par Pharmaceuticals, which began operations in 2001 as part of the Dexa Group, is a rapidly growing pharmaceutical company. It has become one of Indonesia's top 15 largest pharmaceutical companies (based on IQVIA's Q1 2025 combined IPA and IHPA MAT data). The company's facilities are certified by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Portugal's National Authority of Medicines and Health Products (Infarmed). With its diversified product portfolio, advanced manufacturing capabilities, and strong strategic partnerships, PT Ferron continues to expand its market presence and enhance its operational excellence.